← All trials
NCT05293223
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 1, 2021
- Primary completion
- Nov 15, 2022
- Completion date
- Jan 15, 2023
- First posted
- Mar 24, 2022
- Last posted
- Sep 29, 2022
- Enrollment
- 450
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Fundacion HuespedLead sponsor
- Dalhousie UniversityCollaborator
- Fundacion HuespedReponsible party - principal investigator
- Tianjin Cansino Biotechnology IncCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.